SI-BONE Inc
NASDAQ:SIBN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/S
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Valuation Scenarios
If P/S returns to its 3-Year Average (4.2), the stock would be worth $19.42 (57% upside from current price).
| Scenario | P/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 2.7 | $12.36 |
0%
|
| 3-Year Average | 4.2 | $19.42 |
+57%
|
| 5-Year Average | 5.3 | $24.32 |
+97%
|
| Industry Average | 1.7 | $8.03 |
-35%
|
| Country Average | 2.4 | $11.21 |
-9%
|
Forward P/S
Today’s price vs future revenue
| Today's Market Cap | Revenue | Forward P/S | ||
|---|---|---|---|---|
|
$576.6m
|
/ |
Jan 2026
$200.9m
|
= |
|
|
$576.6m
|
/ |
Dec 2026
$235m
|
= |
|
|
$576.6m
|
/ |
Dec 2027
$270.1m
|
= |
|
|
$576.6m
|
/ |
Dec 2028
$311.5m
|
= |
|
Forward P/S shows whether today’s P/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | P/S | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
SI-BONE Inc
NASDAQ:SIBN
|
539.5m USD | 2.7 | -28.5 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
165.7B USD | 15.9 | 56.2 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
163B USD | 3.5 | 25.5 | |
| US |
|
Stryker Corp
NYSE:SYK
|
122.9B USD | 4.8 | 36.8 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
105.1B USD | 2.9 | 22.2 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
86.7B USD | 4.1 | 23.8 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
47.8B USD | 7.5 | 42.9 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
39.8B EUR | 1.7 | 18.2 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
45.3B USD | 10.1 | 41.2 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
42.6B USD | 1.9 | 23.7 | |
| US |
|
Resmed Inc
NYSE:RMD
|
31.6B USD | 5.7 | 20.9 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.2 |
| Median | 2.4 |
| 70th Percentile | 4.1 |
| Max | 4 613 274.2 |
Other Multiples
SI-BONE Inc
Glance View
SI-BONE, Inc. engages in the provision of implantable devices used in the surgical treatment of the sacropelvic anatomy. The company is headquartered in Santa Clara, California and currently employs 352 full-time employees. The company went IPO on 2018-10-17. The firm is focused on the development of implantable devices used in the surgical treatment of sacro-pelvic anatomy. Its invasive surgical implant system, iFuse, is used to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that often causes severe lower back pain. Its iFuse Implant System includes a series of triangular titanium implants and the instruments developed to enable surgeons to perform the procedure. Its iFuse system, which includes its implants and instruments, is designed to address the shortcomings of alternative treatments, including open surgery, non-surgical management, and screw-based and other minimally invasive stabilization and fusion procedures. Its iFuse-3D design allows the surgeons to fill the implant with ground-up bone before implantation, which accelerates bone through-growth and biological fixation. The company also provides other technologies for its surgeons other than iFuse and iFuse-3D.
